PT2864473T - Células estaminais e células pancreáticas úteis para o tratamento de diabetes mellitus dependente de insulina - Google Patents

Células estaminais e células pancreáticas úteis para o tratamento de diabetes mellitus dependente de insulina

Info

Publication number
PT2864473T
PT2864473T PT13733516T PT13733516T PT2864473T PT 2864473 T PT2864473 T PT 2864473T PT 13733516 T PT13733516 T PT 13733516T PT 13733516 T PT13733516 T PT 13733516T PT 2864473 T PT2864473 T PT 2864473T
Authority
PT
Portugal
Prior art keywords
insulin
treatment
diabetes mellitus
dependent diabetes
stem cells
Prior art date
Application number
PT13733516T
Other languages
English (en)
Portuguese (pt)
Inventor
L Rust William
Original Assignee
Seraxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seraxis Inc filed Critical Seraxis Inc
Publication of PT2864473T publication Critical patent/PT2864473T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1329—Cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
PT13733516T 2012-06-26 2013-06-24 Células estaminais e células pancreáticas úteis para o tratamento de diabetes mellitus dependente de insulina PT2864473T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261664259P 2012-06-26 2012-06-26

Publications (1)

Publication Number Publication Date
PT2864473T true PT2864473T (pt) 2019-09-27

Family

ID=48746139

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13733516T PT2864473T (pt) 2012-06-26 2013-06-24 Células estaminais e células pancreáticas úteis para o tratamento de diabetes mellitus dependente de insulina

Country Status (16)

Country Link
US (2) US9968639B2 (enExample)
EP (2) EP3611255A1 (enExample)
JP (2) JP6386453B2 (enExample)
KR (2) KR102058259B1 (enExample)
CN (2) CN104640979B (enExample)
AU (2) AU2013280698B2 (enExample)
BR (1) BR112014031676A2 (enExample)
CA (1) CA2876677C (enExample)
DK (1) DK2864473T3 (enExample)
EA (2) EA033954B1 (enExample)
ES (1) ES2745704T3 (enExample)
IL (2) IL236346B (enExample)
IN (1) IN2015DN00281A (enExample)
PT (1) PT2864473T (enExample)
SG (1) SG11201408717XA (enExample)
WO (1) WO2014004341A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106467918B (zh) * 2015-08-18 2020-07-31 中国科学技术大学先进技术研究院 一种基于人皮肤细胞的胰岛素分泌细胞的诱导方法及应用
CN105434471A (zh) * 2015-11-26 2016-03-30 深圳爱生再生医学科技有限公司 治疗糖尿病的干细胞制剂及其制备方法
WO2019157329A1 (en) * 2018-02-09 2019-08-15 Seraxis, Inc. Pancreatic cells for treating diabetes and methods of generating the same
AU2019360857A1 (en) * 2018-10-15 2021-06-03 Evia Life Sciences Inc. Method for producing stem/precursor cells, by using low molecular weight compound, from cells derived from endodermal tissue or organ
CN114845727B (zh) * 2019-12-11 2025-08-26 国立大学法人东京大学 基于Mycl瞬时表达的可增殖性胰岛前体细胞样细胞的诱导和胰岛素阳性细胞的分化诱导
US20220409855A1 (en) 2021-06-29 2022-12-29 Staffan Holmin Methods of delivering cells and therapeutic agents to organs and extravascular sites
AU2023254488A1 (en) 2022-04-15 2024-12-05 Smartcella Solutions Ab COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS
EP4658761A1 (en) 2023-02-03 2025-12-10 Seraxis, Inc. Therapeutic cells and methods relating to the same
WO2025029826A1 (en) 2023-07-31 2025-02-06 Seraxis, Inc. Modified therapeutics cells and methods relating to the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861313A (en) * 1995-06-07 1999-01-19 Ontogeny, Inc. Method of isolating bile duct progenitor cells
EP1144631A3 (en) 1999-01-07 2002-01-30 Incyte Pharmaceuticals, Inc. Insulin-synthesis genes
US6815203B1 (en) 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
EP1257282A4 (en) 1999-12-06 2003-05-02 Gen Hospital Corp PANCREATIC STEM CELLS AND THEIR USE IN TRANSPLANTATION
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US7371576B2 (en) 2002-09-06 2008-05-13 Reneuron, Inc. CD56 positive human adult pancreatic endocrine progenitor cells
PT1636348E (pt) 2003-06-20 2009-10-21 Vrije Universiteit Brussel Vub Método de gerar ilhotas de células beta a partir de células pancreáticas exócrinas
WO2005086860A2 (en) * 2004-03-09 2005-09-22 Gang Xu Methods for generating insulin-producing cells
US20060029987A1 (en) 2004-08-06 2006-02-09 Applera Corporation Diagnosis of pancreatic cancer by using pancreatic targets
US7807459B2 (en) 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
US20100137202A1 (en) * 2006-07-19 2010-06-03 University Of Florida Research Foundation Compositions for reprogramming a cell and uses therefor
US20100204258A1 (en) 2007-03-12 2010-08-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
WO2009061024A1 (en) 2007-11-09 2009-05-14 Rnl Bio Co., Ltd Method for isolating and culturing adult stem cells derived from human amniotic epithelium
US8470595B2 (en) 2008-04-18 2013-06-25 National University Corporation Nagoya University Mesenchymal stem cell and method for production thereof
JP2011519574A (ja) * 2008-05-09 2011-07-14 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ グラスゴー 細胞ベースの治療に関連する材料および方法
WO2010022395A2 (en) * 2008-08-22 2010-02-25 President And Fellows Of Harvard College Methods of reprogramming cells
AU2009329893A1 (en) * 2008-12-23 2011-06-30 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
US20120263689A1 (en) * 2009-09-10 2012-10-18 The Salk Institute For Biological Studies Adipose-derived induced pluripotent stem cells
RU2663339C1 (ru) * 2010-05-12 2018-08-03 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
WO2012025914A1 (en) * 2010-08-22 2012-03-01 Ramot At Tel-Aviv University Ltd. Induced pluripotent stem cells derived from human pancreatic beta cells
JP6133776B2 (ja) * 2010-08-31 2017-05-24 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の分化
WO2012035539A1 (en) * 2010-09-15 2012-03-22 Ramot At Tel-Aviv University Ltd. Methods of expanding and redifferentiating islet beta cells
US20120135015A1 (en) * 2010-09-28 2012-05-31 Baylor Research Institute Induction of Pancreatic Stem Cells by Transient Overexpression of Reprogramming Factors and PDX1 Selection

Also Published As

Publication number Publication date
CA2876677C (en) 2021-09-07
EA201590088A1 (ru) 2015-04-30
EP2864473B1 (en) 2019-08-21
US9968639B2 (en) 2018-05-15
JP6856586B2 (ja) 2021-04-07
ES2745704T3 (es) 2020-03-03
EA201992135A1 (ru) 2020-02-05
US20150231181A1 (en) 2015-08-20
IL236346B (en) 2019-06-30
AU2019202085A1 (en) 2019-04-18
US20130344594A1 (en) 2013-12-26
JP2015522281A (ja) 2015-08-06
IL236346A0 (en) 2015-02-26
SG11201408717XA (en) 2015-02-27
DK2864473T3 (da) 2019-09-23
CN113265370A (zh) 2021-08-17
EA033954B1 (ru) 2019-12-13
EP3611255A1 (en) 2020-02-19
KR102058259B1 (ko) 2019-12-23
AU2013280698A1 (en) 2015-01-22
WO2014004341A1 (en) 2014-01-03
KR20190141263A (ko) 2019-12-23
IN2015DN00281A (enExample) 2015-06-12
IL266965A (en) 2019-07-31
AU2013280698B2 (en) 2019-01-17
JP2018193394A (ja) 2018-12-06
KR102174581B1 (ko) 2020-11-06
CN104640979B (zh) 2021-05-04
CA2876677A1 (en) 2014-01-03
US9474772B2 (en) 2016-10-25
KR20150036059A (ko) 2015-04-07
IL266965B (en) 2021-08-31
JP6386453B2 (ja) 2018-09-05
CN104640979A (zh) 2015-05-20
EP2864473A1 (en) 2015-04-29
BR112014031676A2 (pt) 2017-10-31

Similar Documents

Publication Publication Date Title
SG11201408717XA (en) Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
IL269322B (en) Methylphenidate-medications, processes for their preparation and use
ZA201403795B (en) Formulations for the treatment of diabetes
PL2934404T3 (pl) Elastyczny laminat i sposób wytwarzania elastycznego laminatu
IL220889A0 (en) Methods of treating diabetes with dll4 antagonists
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
PL2707017T3 (pl) Liksisenatyd i metformina do leczenia cukrzycy typu 2
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
AP2013007179A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
IL235484A0 (en) Glucokinase-activating preparations for the treatment of diabetes
PT3347027T (pt) Neo-ilhotas que compreendem células estaminais e de ilhotas e tratamento de diabetes mellitus com as mesmas
IL223289A0 (en) Treatment of type 2 diabetes
EP2704702A4 (en) COMPOSITION AND METHOD OF TREATING DIABETES
PL2936151T3 (pl) Sposoby leczenia i/lub ograniczania rozwoju cukrzycy
ZA201408065B (en) Compositions and methods for the treatment of diabetes
IL233004A0 (en) Treatment of type I and type II diabetes
IL232294A0 (en) Preparations for the treatment of diabetes
AU2010902914A0 (en) Treatment of diabetes